Logo image of SMTI

SANARA MEDTECH INC (SMTI) Stock Fundamental Analysis

NASDAQ:SMTI - Nasdaq - US79957L1008 - Common Stock - Currency: USD

31.5  +0.62 (+2.01%)

Fundamental Rating

3

Taking everything into account, SMTI scores 3 out of 10 in our fundamental rating. SMTI was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of SMTI have multiple concerns. SMTI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

SMTI had negative earnings in the past year.
In the past year SMTI has reported a negative cash flow from operations.
In the past 5 years SMTI always reported negative net income.
SMTI had a negative operating cash flow in each of the past 5 years.
SMTI Yearly Net Income VS EBIT VS OCF VS FCFSMTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

SMTI has a better Return On Assets (-10.97%) than 60.32% of its industry peers.
SMTI's Return On Equity of -24.53% is in line compared to the rest of the industry. SMTI outperforms 59.26% of its industry peers.
Industry RankSector Rank
ROA -10.97%
ROE -24.53%
ROIC N/A
ROA(3y)-9.93%
ROA(5y)-19.18%
ROE(3y)-17.7%
ROE(5y)-29.97%
ROIC(3y)N/A
ROIC(5y)N/A
SMTI Yearly ROA, ROE, ROICSMTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

The Gross Margin of SMTI (90.61%) is better than 98.41% of its industry peers.
SMTI's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SMTI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5Y0.2%
SMTI Yearly Profit, Operating, Gross MarginsSMTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

3

2. Health

2.1 Basic Checks

SMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SMTI has more shares outstanding
SMTI has more shares outstanding than it did 5 years ago.
SMTI has a worse debt/assets ratio than last year.
SMTI Yearly Shares OutstandingSMTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
SMTI Yearly Total Debt VS Total AssetsSMTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 3.93 indicates that SMTI is not in any danger for bankruptcy at the moment.
SMTI has a better Altman-Z score (3.93) than 76.19% of its industry peers.
A Debt/Equity ratio of 0.78 indicates that SMTI is somewhat dependend on debt financing.
SMTI has a Debt to Equity ratio of 0.78. This is in the lower half of the industry: SMTI underperforms 71.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Altman-Z 3.93
ROIC/WACCN/A
WACC8.88%
SMTI Yearly LT Debt VS Equity VS FCFSMTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 2.18 indicates that SMTI has no problem at all paying its short term obligations.
SMTI has a worse Current ratio (2.18) than 61.38% of its industry peers.
SMTI has a Quick Ratio of 2.00. This is a normal value and indicates that SMTI is financially healthy and should not expect problems in meeting its short term obligations.
SMTI has a Quick ratio (2.00) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.18
Quick Ratio 2
SMTI Yearly Current Assets VS Current LiabilitesSMTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

5

3. Growth

3.1 Past

The earnings per share for SMTI have decreased strongly by -127.46% in the last year.
SMTI shows a strong growth in Revenue. In the last year, the Revenue has grown by 33.36%.
Measured over the past years, SMTI shows a very strong growth in Revenue. The Revenue has been growing by 49.08% on average per year.
EPS 1Y (TTM)-127.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-96.19%
Revenue 1Y (TTM)33.36%
Revenue growth 3Y53.13%
Revenue growth 5Y49.08%
Sales Q2Q%26.42%

3.2 Future

Based on estimates for the next years, SMTI will show a very negative growth in Earnings Per Share. The EPS will decrease by -25.84% on average per year.
The Revenue is expected to grow by 13.59% on average over the next years. This is quite good.
EPS Next Y-68.66%
EPS Next 2Y-25.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year21.95%
Revenue Next 2Y13.59%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SMTI Yearly Revenue VS EstimatesSMTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
SMTI Yearly EPS VS EstimatesSMTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

1

4. Valuation

4.1 Price/Earnings Ratio

SMTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SMTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SMTI Price Earnings VS Forward Price EarningsSMTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

62.96% of the companies in the same industry are more expensive than SMTI, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 286.43
SMTI Per share dataSMTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

SMTI's earnings are expected to decrease with -25.84% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.84%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for SMTI!.
Industry RankSector Rank
Dividend Yield N/A

SANARA MEDTECH INC

NASDAQ:SMTI (5/16/2025, 8:22:49 PM)

31.5

+0.62 (+2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners11.17%
Inst Owner Change-0.56%
Ins Owners7.64%
Ins Owner Change0.35%
Market Cap280.04M
Analysts82.5
Price Target49.47 (57.05%)
Short Float %7.03%
Short Ratio7.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.61%
Min EPS beat(2)-53.45%
Max EPS beat(2)46.24%
EPS beat(4)1
Avg EPS beat(4)-73.19%
Min EPS beat(4)-194.12%
Max EPS beat(4)46.24%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.3%
Min Revenue beat(2)-0.04%
Max Revenue beat(2)2.64%
Revenue beat(4)2
Avg Revenue beat(4)1.08%
Min Revenue beat(4)-1.77%
Max Revenue beat(4)3.47%
Revenue beat(8)3
Avg Revenue beat(8)-2.71%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-90.57%
EPS NY rev (1m)-6.2%
EPS NY rev (3m)-94.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.23
P/FCF N/A
P/OCF N/A
P/B 7.11
P/tB N/A
EV/EBITDA 286.43
EPS(TTM)-1.34
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS9.75
BVpS4.43
TBVpS-0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.97%
ROE -24.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.61%
FCFM N/A
ROA(3y)-9.93%
ROA(5y)-19.18%
ROE(3y)-17.7%
ROE(5y)-29.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5Y0.2%
F-Score4
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF N/A
Debt/EBITDA 29.81
Cap/Depr 4.66%
Cap/Sales 0.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.18
Quick Ratio 2
Altman-Z 3.93
F-Score4
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)14.51%
Cap/Depr(5y)146.81%
Cap/Sales(3y)0.77%
Cap/Sales(5y)3.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-127.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-96.19%
EPS Next Y-68.66%
EPS Next 2Y-25.84%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)33.36%
Revenue growth 3Y53.13%
Revenue growth 5Y49.08%
Sales Q2Q%26.42%
Revenue Next Year21.95%
Revenue Next 2Y13.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y92.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.27%
OCF growth 3YN/A
OCF growth 5YN/A